Endo-Impax settlement procompetitive, eased access to generic Opana ER, judge rules
A settlement by Endo Pharmaceuticals with Impax Laboratories didn't violate antitrust law because “the evidence proves that the Endo-Impax Settlement was, on balance, procompetitive,” a judge ruled on Friday in dismissing...To view the full article, register now.
Already a subscriber? Click here to view full article